Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Rojo

Showing results (111-120 of 146) with videos related to

Pageof 15
Sort By:
Trials|June 27, 2022
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trialPablo Rojo, Cinta Moraleda, Alfredo Tagarro, et al.
Medicine|April 13, 2021
Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthoodBeatriz Ruiz-Saez, Manuela Martín-Bejarano García, Ana Martinez de Aragon, et al.
The Pediatric Infectious Disease Journal|October 19, 2019
Role of Magnetic Resonance Imaging and Cranial Ultrasonography in Congenital Cytomegalovirus InfectionDaniel Blázquez-Gamero, María Soriano-Ramos, Ana Martínez de Aragón, et al.
Frontiers in Immunology|April 18, 2022
Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive TherapyAlessandra Ruggiero, Giuseppe Rubens Pascucci, Nicola Cotugno, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2026
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trialJames Wyncoll, Rujirek Kamolrattana, Moherndran Archary, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 2016
Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia, Eliane Rohner, Kurt Schmidlin, et al.
The Lancet. HIV|August 19, 2024
The long wait for long-acting HIV prevention and treatment formulationsWillem Daniel Francois Venter, Monica Gandhi, Simiso Sokhela, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
Frontiers in Immunology|March 6, 2024
Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ARTKathleen Gärtner, Sara Domínguez-Rodríguez, Judith Heaney, et al.
Pageof 15

Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
Trials|June 27, 2022
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trialPablo Rojo, Cinta Moraleda, Alfredo Tagarro, et al.
Medicine|April 13, 2021
Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthoodBeatriz Ruiz-Saez, Manuela Martín-Bejarano García, Ana Martinez de Aragon, et al.
The Pediatric Infectious Disease Journal|October 19, 2019
Role of Magnetic Resonance Imaging and Cranial Ultrasonography in Congenital Cytomegalovirus InfectionDaniel Blázquez-Gamero, María Soriano-Ramos, Ana Martínez de Aragón, et al.
Frontiers in Immunology|April 18, 2022
Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive TherapyAlessandra Ruggiero, Giuseppe Rubens Pascucci, Nicola Cotugno, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2026
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trialJames Wyncoll, Rujirek Kamolrattana, Moherndran Archary, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 2016
Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia, Eliane Rohner, Kurt Schmidlin, et al.
The Lancet. HIV|August 19, 2024
The long wait for long-acting HIV prevention and treatment formulationsWillem Daniel Francois Venter, Monica Gandhi, Simiso Sokhela, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
Frontiers in Immunology|March 6, 2024
Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ARTKathleen Gärtner, Sara Domínguez-Rodríguez, Judith Heaney, et al.
Pageof 15